What are the clinical presentation, diagnostic criteria, and first-line treatment options for hairy cell leukemia?

Hairy Cell Leukemia: Clinical Presentation, Diagnosis, and Treatment

Clinical Presentation

Patients with hairy cell leukemia most commonly present with incidental pancytopenia discovered on routine blood work, though fatigue, infection, and splenomegaly are also frequent findings 1, 2.

Key clinical features to identify:

• Pancytopenia (most common presentation in modern practice)
• Monocytopenia (relatively sensitive and specific finding) 1
• Splenomegaly (historically present in ~90% of cases, now less frequent due to earlier detection) 1
• Constitutional symptoms: fatigue, weight loss, abdominal discomfort 3, 4
• Infectious complications due to neutropenia 4

The disease predominantly affects middle-aged men and is often detected incidentally during routine laboratory evaluation 3.

---

Diagnostic Criteria

The diagnosis of classic HCL requires morphologic identification of hairy cells, an immunophenotypic score of 3-4, bone marrow biopsy confirmation, and demonstration of BRAF V600E mutation 2, 5, 6.

Essential Diagnostic Steps:

1. Peripheral blood smear: Look for lymphoid cells with characteristic cytoplasmic projections ("hairy cells") 1, 7

2. Immunophenotyping (flow cytometry or IHC) - Classic HCL shows:

   • CD5–, CD10–, CD11c+, CD20+ (bright), CD22+, CD25+, CD103+, CD123+, cyclin D1+, annexin A1+, CD200+ (bright) 2
   • HCL immunologic score of 3 or 4 based on CD11c, CD103, CD123, and CD25 expression 5, 6

3. Bone marrow evaluation:

   • Trephine biopsy (often "dry tap" due to fibrosis) 1
   • Immunohistochemical stains for CD20, annexin-1, BRAF V600E (VE1 antibody) 1
   • ~10% show hypocellular marrow at diagnosis 1

4. BRAF V600E mutation testing: Present in >95% of classic HCL cases 8, 5

   • Critical for distinguishing classic HCL from HCL-variant (which lacks BRAF V600E) 2, 8
   • Essential for considering targeted BRAF inhibitor therapy 1, 9

Important Distinction:

HCL-variant (HCLv) must be differentiated from classic HCL as it follows a more aggressive course and responds poorly to standard therapy 2. HCLv is characteristically CD25–, CD123–, annexin A1–, and BRAF V600E–negative 2.

Prognostic Factors:

• IGHV4-34 rearrangement: Associated with poor prognosis and poor response to purine analogs 2, 5, 6
• TP53 mutations: Poor prognosis 5
• Unmutated IGHV profile (20% of cases): Associated with poor prognosis 9
• Large splenomegaly, leukocytosis, high peripheral hairy cell count 5, 6

---

First-Line Treatment

Purine analog chemotherapy is the established first-line treatment for symptomatic HCL, with chemoimmunotherapy (cladribine plus rituximab) increasingly becoming the gold standard 5, 9, 6.

Treatment Indications:

Treat only symptomatic patients 5, 6. Watch-and-wait is appropriate for ~10% of asymptomatic patients 10.

Indications for treatment include:

• Disease-related symptoms (fatigue, infections)
• Significant cytopenias
• Progressive splenomegaly
• Declining hematologic parameters 1, 2

First-Line Treatment Options:

1. Cladribine-based regimens (preferred):

• Cladribine + Rituximab: Now considered the gold standard first-line therapy 5, 9
• Cladribine monotherapy: Continuous infusion or subcutaneous injection 1

2. Pentostatin: Intravenous administration 1

Response Assessment Timing:

• For cladribine: Bone marrow evaluation should not be performed before 4 months post-therapy 2
• For pentostatin: Evaluate after blood counts normalize and splenomegaly resolves 2

Anti-Infective Prophylaxis:

Critical to prevent opportunistic infections during treatment 2:

• Herpes virus prophylaxis (acyclovir or equivalent) for minimum 2 months and until CD4 ≥200 cells/mm³
• PJP prophylaxis (sulfamethoxazole/trimethoprim or equivalent) for minimum 2 months and until CD4 ≥200 cells/mm³
• Broad-spectrum antibacterial coverage during neutropenia

Relapsed/Refractory Disease Options:

For patients who relapse or are refractory to first-line therapy 5, 6:

• BRAF inhibitors + rituximab
• MEK inhibitors
• Recombinant immunoconjugates targeting CD22
• BTK inhibitors
• BCL-2 inhibitors

---

Critical Pitfalls to Avoid

1. Do not misdiagnose HCL as lymphoplasmacytic lymphoma or CLL - this leads to inappropriate multi-agent chemotherapy (like R-CHOP) with excessive toxicity and poor outcomes 4

2. Do not use BRAF inhibitors in patients with non-canonical BRAF mutations - these are contraindicated 9

3. Do not evaluate bone marrow response too early after cladribine - wait at least 4 months 2

4. Do not forget infection prophylaxis - HCL patients are severely immunocompromised during treatment 2

5. Always distinguish classic HCL from HCL-variant - treatment approaches and prognosis differ significantly 2, 8

6. Monitor for second malignancies - HCL patients have increased risk, possibly related to disease and/or treatment 10